On March 18, 2022, Apexigen, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing a new generation of antibody therapeutics for oncology, and Brookline Capital Acquisition Corp., a special purpose acquisition company (SPAC), announced they have entered into a definitive business combination agreement, PIPE financing, and equity line facility. Upon closing of the transaction, Brookline Capital Acquisition Corp. will be renamed Apexigen, Inc. and the combined company expects to list its stock on Nasdaq under the ticker symbol “APGN.” Wilson Sonsini is advising Apexigen on the transaction.
This transaction brings Apexigen public and strengthens the advancement of the Phase 2 development of the lead program, sotigalimab, as well as maximizes the therapeutic potential of Apexigen’s APXiMAB™ antibody discovery platform and innovative pipeline of other antibody therapeutics. Together with Brookline Capital Acquisition Corp., Apexigen looks forward to driving sotigalimab through Phase 2 development and delivering on the shared vision to overcome outstanding challenges in oncology.
The Wilson Sonsini team that advised Apexigen on the transaction includes:
Corporate/M&A
Ken Clark
Rob Ishii
Michael Coke
Lance Brady
Brendan Mahan
Sara Dunton
Tracy Sevush
Niharika Tawde
Nichola Rohr
Kaleigh Hawkins-Schulz
Technology Transactions - Biotech
Norm Hovijitra
Kexi Wang
Sai Upadhyayula
Corporate Finance
Michael Occhiolini
Employee Benefits and Compensation
Scott McCall
Mark Cornillez-Ty
Jason Chan
Employment Litigation
Matt Gorman
FDA Regulatory
David Hoffmeister
Eva Yin
Antitrust
Todd Hahn
Privacy and Cybersecurity
Cédric Burton
Nikolaos Theodorakis
For more information, please see Apexigen's press release.